Core Viewpoint - The selection of Chen Shaoliang as a candidate for the Chinese Academy of Engineering highlights the growing recognition of Chinese medical professionals in the field of cardiovascular intervention, reflecting the country's emphasis on original medical innovations and high-end medical device localization [1][5]. Group 1: Candidate Selection - The Chinese Academy of Engineering announced a total of 660 valid candidates for the 2025 academician election, with 91 candidates from the Medical and Health Sciences Division [1]. Group 2: Professional Achievements - Chen Shaoliang has made significant contributions to clinical, research, and educational work in cardiology, holding important academic positions in various prestigious organizations such as the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) [3]. - He has published over 300 SCI-indexed papers and has been recognized as one of the most cited scholars in the Chinese cardiovascular field, with some papers cited over a thousand times [4]. Group 3: Innovations and Contributions - Chen's innovative techniques, such as the "DK CRUSH" method for treating coronary bifurcation lesions, have gained international recognition, being included in global guidelines by the European Society of Cardiology [3][4]. - His work on the percutaneous pulmonary artery denervation (PADN) technique was incorporated into the ESC/ERS guidelines for pulmonary hypertension, marking a significant achievement for Chinese medical innovation [4]. Group 4: Alignment with National Policies - Chen's achievements align with national strategies like "Healthy China 2030" and "Technological Self-Reliance," showcasing a complete innovation path from clinical needs to international guideline recognition and industrial transformation [5]. - His selection as a candidate not only acknowledges his personal contributions but also reflects the rising global influence of Chinese medical innovations [5].

Core Insights - Pamu Medical has successfully completed a new round of financing amounting to tens of millions of dollars, led by EQT, a European private equity firm, with continued support from Sequoia Capital [1][3] - The funds raised will primarily be used for Pamu Medical's overseas market expansion, including global clinical registration, product indication expansion, and deepening industrialization systems [1][4] Company Development - Pamu Medical's CEO, Lian Jia, emphasized the importance of results-oriented progress and the commitment to advancing product transformation and global layout, ensuring that valuable Chinese original technologies can operate in broader markets [3][7] - Since its establishment in 2013, Pamu Medical has focused on global innovation, creating a closed loop of "R&D - Clinical - Market" [3][4] - The company's core technology, Percutaneous Pulmonary Artery Denervation (PADN), has been included in authoritative guidelines and has received CE-MDR certification from the EU, as well as humanitarian device exemption (HUD) from the FDA and market approval from the National Medical Products Administration (NMPA) in 2023 [3][4] Product and Market Strategy - Pamu Medical is constructing a global development pathway that is "verifiable, sustainable, and integrable into international standards," with successful commercialization of PADN products in China and ongoing efforts to penetrate international markets [4][5] - The recent financing will support Pamu Medical's strategy of "technology internationalization + path standardization," solidifying its position as a platform for Chinese original medical technology in the global healthcare system [4][5] Investor Perspective - EQT's Executive Director, Zoe Zhu, expressed confidence in Pamu Medical's innovative capabilities in the medical device sector, highlighting the potential of the PADN product in addressing unmet needs in the fields of pulmonary hypertension and heart failure [5][6] - Pamu Medical's Chairman, Cynthia Chen, acknowledged the challenges of establishing Chinese original technology as international standards but expressed confidence in the company's commitment to clinical value and innovation for global patients [7]